

## Anti-ENTPD1 / CD39 Reference Antibody (TTX-030)

Recombinant Antibody Catalog # APR10301

## **Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	<u>P49961</u>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4
Calculated MW	57965

## **Additional Information**

Target/Specificity	ENTPD1 / CD39
Endotoxin Conjugation	Unconjugated
Expression system	CHO Cell
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

## **Protein Information**

Name	ENTPD1 ( <u>HGNC:3363</u> )
Function	Catalyzes the hydrolysis of both di- and triphosphate nucleotides (NDPs and NTPs) and hydrolyze NTPs to nucleotide monophosphates (NMPs) in two distinct successive phosphate-releasing steps, with NDPs as intermediates and participates in the regulation of extracellular levels of nucleotides (Probable) (PubMed: <u>8529670</u> , PubMed: <u>8626624</u> , PubMed: <u>8996251</u> ). By hydrolyzing proinflammatory ATP and platelet-activating ADP to AMP, it blocks platelet aggregation and supports blood flow (PubMed: <u>8955160</u> , PubMed: <u>8996251</u> ).
Cellular Location	Membrane; Multi-pass membrane protein. Membrane, caveola
Tissue Location	Expressed primarily on activated lymphoid cells (PubMed:7930580). Also expressed in endothelial tissues (PubMed:8955160). Highly expressed in placenta, lung, skeletal muscle, kidney (PubMed:8955160).



Anti-ENTPD1 / CD39 Reference Antibody (TTX-030) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%

The purity of Anti-ENTPD1 / CD39 Reference Antibody (TTX-030)is more than 99.83% ,determined by SEC-HPLC.

TTX-030 inhibited the tumor growth of MOLP-8 on NCG mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 99.3% at 20 mpk at D25.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.